ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Breast Cancer

Pertuzumab Combo Improved Invasive DFS in HER2-Positive Breast Cancer

The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease–free survival in patients with HER2-positive early breast cancer.

Gunter von Minckwitz, MD, PhD, presenting results of the trial; photo © ASCO/Scott Morgan 2017

Breast Cancer

Limiting Medicaid enrollment has the potential for negative health impacts, in particular among low-income women with a diagnosis of breast cancer, according to a new study.

A biosimilar to trastuzumab known as CT-P6 showed equivalent efficacy and similar toxicity to the original agent in patients with HER2-positive breast cancer.

The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy.

Patients with HER2-negative breast cancer with residual invasive disease following neoadjuvant chemotherapy benefit from adjuvant treatment with capecitabine.

The use of a four-gene signature identified a series of subgroups of triple-negative breast cancer, including one subtype that was responsive to platinum-based chemotherapy in the metastatic setting.

For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy.

Dual HER2 blockade was superior to single blockade in postmenopausal women with HER2-positive, HR-positive metastatic breast cancer.

Pages

Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.